Protagonist's (PTGX) Economics Can Change After Takeda Opt-out - Citizens

December 12, 2025 4:54 AM EST Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $102.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login